Bachem brings scientific expertise to Spring 2024 conferences

Peptide and oligonucleotide technology specialist Bachem will be at three of the world’s most important biopharma events taking place in mid-March across Europe, North America and Asia.
 
As an exhibitor and scientific contributor, Bachem will use all three events to showcase its leading-edge capabilities as a peptide and oligonucleotide manufacturer.
 
Bio-Europe Spring
Opening on March 18th, Bachem will be a Gold Sponsor and leading participant in the BIO Europe Spring 2024 event in Barcelona’s CCIB congress centre.
 
The three-day event facilitates networking for companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.
 
The conference is expected to attract 2,500 delegates and 70 exhibitors representing more than 1,400 companies from 50 countries worldwide. It will feature more than 20 workshops and panels with over 3,600 licensing opportunities posted.
 
Riccardo Bernasconi, Business Development Director, will represent the company in the widespread networking activities.
 
DCAT Week
Opening on the same day on the other side of the Atlantic, Bachem will also be a leading presence at the prestigious DCAT week in New York City, hosting presentations and meetings from Rooms 1501 & 1502 at the main conference venue, the Lotte New York Palace Hotel on Madison Avenue.
The Drug, Chemical & Associated Technologies Association (DCAT), founded in 1890, has become North America’s premier business development association for companies that manufacture, distribute or provide services to the pharmaceutical and chemical industries.
 
The event is expected to attract over 10,000 attendees, with the majority being C-Suite executives and high-level decision makers, representing 700 companies from more than 50 nations worldwide.
 
Bachem is sending a team of 8 people to the event, headed by CEO Thomas Meier. The team also includes CCO Torsten Wöhr, VP Head of Global Sales André Casagrande, Senior Director and Head of Generics Eric Bouillet, Directors of Sales Generics Pascal Hess and Sergey Malashikhin, VP Head of Global Strategic Alliances Boris Corpataux, and Director Product Management Tycho Leifels.
 
The week will conclude on Thursday, 21st March, with the 96th DCAT Annual Dinner held in the Grand Ballroom of the New York Hilton.
 
TIDES Asia
The day after both these events open, Bachem will also attend a third conference in Japan. At this TIDES Asia 2024 meeting, it will be an exhibitor from Booth 33 at the Westin Miyako Hotel in Kyoto, displaying the range of its offerings in peptides and oligonucleotides for drug substance development and manufacturing.
 
TIDES Asia is expected to attract more than 300 oligonucleotide and peptide experts across Asia, Europe and North America. It will feature numerous keynote addresses from leading practitioners in the biologics field as well as workshops on early drug development and CMC of oligonucleotide therapeutics and strategies and techniques to improve the drug-like properties of peptides throughout the product lifecycle.
 
Dr Daniel Samson, VP Head of Oligonucleotides at Bachem, will also contribute to the scientific agenda at the meeting with a presentation on day two (Track 1, March 20, 1450 hrs.) on ‘Going Large-scale with Manufacturing of Oligonucleotides’ which will review the challenges involved in industrial scale oligomer production.
 
Bachem will also be represented in Kyoto by Sales Manager Generics Ito Aya, Head of Asia Pacific Business Development Naoki Yamamoto, VP Head Global Business Chris McGee, Project Manager Daichi Na Su and Sales Assistant Keiko Nomura.
 
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
 
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
 
For further information, see

https://www.bachem.com/